• Apogee Therapeutics Chief Medical Officer Carl Dambkowski sold 5,500 shares on Aug. 5 at USD 134.17.
• He exercised stock options for 4,125 shares the same day at USD 22.86.
• Directly held common stock ended at 168,498 shares.
• Directly held stock options ended at 110,665.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-092838), on August 07, 2026, and is solely responsible for the information contained therein.